Anika Therapeutics introduces Cingal as only approved HA and corticosteroid combination for OA pain

Anika Therapeutics introduces Cingal as only approved HA and corticosteroid combination for OA pain
Anika Therapeutics launches Cingal therapy

Anika Therapeutics has announced that Cingal is the only approved combination of hyaluronic acid and corticosteroid for osteoarthritis pain management.

The product is positioned as fast-acting, long-lasting, and delivering consistent results, backed by clinical evidence. However, Cingal is not currently available in the U.S., according to the company.

Anika Therapeutics recently launched Hyaff, a proprietary hyaluronic acid derivative developed for regenerative tendon and cartilage repair. The company has also marked its commitment to research by celebrating Clinical Trials Day and advancing patient outcomes. Anika continues to focus on clinical innovation in the musculoskeletal health sector.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.
Weekly Top Bonuses
up to $2,500
deposit bonus for all clients
CLAIM BONUS
Your capital is at risk.